Altretamine

Altretamine
Clinical data
Trade names	Hexalen
Other names	2,4,6-Tris(dimethylamino)-1,3,5-triazine
AHFS/Drugs.com	Monograph
MedlinePlus	a601200
License data	US FDA: Altretamine;
Pregnancy; category	AU: D;
Routes of; administration	Oral (capsules)
ATC code	L01XX03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Protein binding	94%
Metabolism	Extensive liver
Metabolites	Pentamethylmelamine, tetramethylmelamine
Elimination half-life	4.7–10.2 hours
Identifiers
	IUPAC name N2,N2,N4,N4,N6,N6-Hexamethyl-1,3,5-triazine-2,4,6-triamine;
CAS Number	645-05-6 ;
PubChem CID	2123;
IUPHAR/BPS	7112;
DrugBank	DB00488 ;
ChemSpider	2038 ;
UNII	Q8BIH59O7H;
KEGG	D02841 ;
ChEBI	CHEBI:24564 ;
ChEMBL	ChEMBL1455 ;
CompTox Dashboard (EPA)	DTXSID4022579 ;
ECHA InfoCard	100.010.391
Chemical and physical data
Formula	C9H18N6
Molar mass	210.285 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c(nc(nc1N(C)C)N(C)C)N(C)C;
	InChI InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3 ; Key:UUVWYPNAQBNQJQ-UHFFFAOYSA-N ;
	(verify)

Altretamine (trade name Hexalen), also called hexamethylmelamine, is an antineoplastic agent. It was approved by the U.S. FDA in 1990.